Please provide your email address to receive an email when new articles are posted on . Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) is an option after any intraocular surgery ...
January 15, 2026 - PRESSADVANTAGE - Lucent Vision has published a new educational resource titled “What Practice Offers ...
SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
Cataract surgery remains one of the most frequently performed ophthalmic procedures worldwide, with continual refinements in surgical methods and intraocular lens (IOL) technology contributing to ...
In this Healio Video Perspective from Hawaiian Eye 2026, Michael Greenwood, MD, of Vance Thompson Vision, discusses the ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
According to a recent groundbreaking study published in the journal Science Robotics by Chinese researchers, a new autonomous ...
SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
Q: What is the payment policy for an Astigmatism-Correcting Intraocular Lens (A-C-IOL) inserted following removal of a cataract in a hospital or ambulatory surgical center? CMS: The payment policy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results